Should DCGI (Drug Controller General of India) take back febuxostat drug from the market?

By  Dr. KK Aggarwal

Should DCGI (Drug Controller General of India) take back febuxostat drug from the market?

Dr. K K Aggarwal, President Heart Care Foundation of India and Group Editor in Chief MEDtalks, will talk on the topic whether DCGI (Drug Controller General of India) should withdraw febuxostat from the market in this video. Febuxostat is given to reduce uric acid in the body. It is often misused drug in our country. If the uric acid levels are more than 10 and patient is asymptomatic then no need to treat them. High uric acid is the indicator of metabolic syndrome. It is been rejected twice by USFDA stating that it causes cardiovascular complications.

user
Dr. KK Aggarwal

Recipient of Padma Shri, Vishwa Hindi Samman, National Science Communication Award and Dr B C Roy National Award, Dr Aggarwal is a physician, cardiologist, spiritual writer and motivational speaker. He was the Past President of the Indian Medical Association and President of Heart Care Foundation of India. He was also the Editor in Chief of the IJCP Group, Medtalks and eMediNexus

 More FAQs by Dr. KK Aggarwal

Faq square banner
One More Hygiene Practice to Prevent Coronavirus
Faq square banner
बचà¥à¤šà¥‹à¤‚ को मिलेगी कोवैकà¥à¤¸à¤¿à¤¨ | Vaccine For Children in H
Faq square banner
कोरोना के दो नठटीके और गोली के बारे मेà

Please login to comment on this article

Logo

Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks

Quick Links

Useful Links

Medbytes FAQ
About Us
Medtalks TV
Contact Us
Webinars
Privacy Policy
CMEs
Terms And Conditions
Conferences

Connect With Us